S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Stock market today: Asian stocks follow Wall St up after strong US jobs report
Laser breakthrough could send stock soaring 2,467% (Ad)
US Navy says Iran Revolutionary Guard fast-attack boats 'harassed' ship in Strait of Hormuz
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Greek authorities rescue 91 migrants from river islet on border with Turkey
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Stop Trading Like A Turtle (Ad)
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
Switzerland's UBS says it could complete Credit Suisse takeover on June 12
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Stock market today: Asian stocks follow Wall St up after strong US jobs report
Laser breakthrough could send stock soaring 2,467% (Ad)
US Navy says Iran Revolutionary Guard fast-attack boats 'harassed' ship in Strait of Hormuz
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Greek authorities rescue 91 migrants from river islet on border with Turkey
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Stop Trading Like A Turtle (Ad)
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
Switzerland's UBS says it could complete Credit Suisse takeover on June 12
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Stock market today: Asian stocks follow Wall St up after strong US jobs report
Laser breakthrough could send stock soaring 2,467% (Ad)
US Navy says Iran Revolutionary Guard fast-attack boats 'harassed' ship in Strait of Hormuz
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Greek authorities rescue 91 migrants from river islet on border with Turkey
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Stop Trading Like A Turtle (Ad)
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
Switzerland's UBS says it could complete Credit Suisse takeover on June 12
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Stock market today: Asian stocks follow Wall St up after strong US jobs report
Laser breakthrough could send stock soaring 2,467% (Ad)
US Navy says Iran Revolutionary Guard fast-attack boats 'harassed' ship in Strait of Hormuz
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Greek authorities rescue 91 migrants from river islet on border with Turkey
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Stop Trading Like A Turtle (Ad)
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
Switzerland's UBS says it could complete Credit Suisse takeover on June 12
NASDAQ:VCEL

Vericel (VCEL) Stock Forecast, Price & News

$32.93
+0.27 (+0.83%)
(As of 06/2/2023 08:49 PM ET)
Compare
Today's Range
$32.49
$33.34
50-Day Range
$28.16
$35.17
52-Week Range
$17.30
$35.73
Volume
252,700 shs
Average Volume
342,275 shs
Market Capitalization
$1.57 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.25

Vericel MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
13.1% Upside
$37.25 Price Target
Short Interest
Bearish
11.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.29) to $0.07 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.00 out of 5 stars

Medical Sector

959th out of 980 stocks

Biological Products, Except Diagnostic Industry

162nd out of 163 stocks


VCEL stock logo

About Vericel (NASDAQ:VCEL) Stock

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Receive VCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter.

VCEL Stock News Headlines

Vericel (NASDAQ:VCEL) Reaches New 52-Week High at $35.53
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
BTIG Issues a Hold Rating on Vericel (VCEL)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
H.C. Wainwright Keeps Their Buy Rating on Vericel (VCEL)
Vericel (VCEL) Scheduled to Post Earnings on Wednesday
Vericel Corporation (VCEL) Q4 Earnings Surpass Estimates
See More Headlines

VCEL Price History

VCEL Company Calendar

Last Earnings
2/23/2023
Today
6/04/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VCEL
Employees
281
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$37.25
High Stock Price Forecast
$42.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+13.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-16,710,000.00
Pretax Margin
-9.68%

Debt

Sales & Book Value

Annual Sales
$163.70 million
Book Value
$4.08 per share

Miscellaneous

Free Float
45,092,000
Market Cap
$1.57 billion
Optionable
Optionable
Beta
1.77

Social Links


Key Executives

  • Dominick C. Colangelo
    President, Chief Executive Officer & Director
  • Michael HalpinMichael Halpin
    Chief Operating Officer
  • Joseph A. Mara
    Chief Financial Officer & Treasurer
  • Jonathan Mark HopperJonathan Mark Hopper
    Chief Medical Officer
  • Sean C. FlynnSean C. Flynn
    Secretary, Senior Vice President & General Counsel













VCEL Stock - Frequently Asked Questions

Should I buy or sell Vericel stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VCEL shares.
View VCEL analyst ratings
or view top-rated stocks.

What is Vericel's stock price forecast for 2023?

4 analysts have issued 1-year price targets for Vericel's stock. Their VCEL share price forecasts range from $34.00 to $42.00. On average, they anticipate the company's stock price to reach $37.25 in the next twelve months. This suggests a possible upside of 13.1% from the stock's current price.
View analysts price targets for VCEL
or view top-rated stocks among Wall Street analysts.

How have VCEL shares performed in 2023?

Vericel's stock was trading at $26.34 at the beginning of the year. Since then, VCEL stock has increased by 25.0% and is now trading at $32.93.
View the best growth stocks for 2023 here
.

When is Vericel's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our VCEL earnings forecast
.

How were Vericel's earnings last quarter?

Vericel Co. (NASDAQ:VCEL) posted its earnings results on Thursday, February, 23rd. The biotechnology company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.10. The biotechnology company had revenue of $52.70 million for the quarter, compared to the consensus estimate of $52.95 million. Vericel had a negative trailing twelve-month return on equity of 9.26% and a negative net margin of 10.11%. The business's revenue was up 10.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.09 EPS.

What guidance has Vericel issued on next quarter's earnings?

Vericel issued an update on its FY 2023 earnings guidance on Friday, May, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $184.00 million-$192.00 million, compared to the consensus revenue estimate of $186.54 million.

What is Nick Colangelo's approval rating as Vericel's CEO?

6 employees have rated Vericel Chief Executive Officer Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among the company's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Vericel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA).

What is Vericel's stock symbol?

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Who are Vericel's major shareholders?

Vericel's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (15.66%), Brown Capital Management LLC (14.81%), RTW Investments LP (6.92%), State Street Corp (5.74%), Conestoga Capital Advisors LLC (5.01%) and Fisher Asset Management LLC (3.66%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Jonathan Siegal, Michael Halpin, Paul K Wotton, Robert L Md Zerbe, Sean C Flynn and Steven C Gilman.
View institutional ownership trends
.

How do I buy shares of Vericel?

Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vericel's stock price today?

One share of VCEL stock can currently be purchased for approximately $32.93.

How much money does Vericel make?

Vericel (NASDAQ:VCEL) has a market capitalization of $1.57 billion and generates $163.70 million in revenue each year. The biotechnology company earns $-16,710,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

How many employees does Vericel have?

The company employs 281 workers across the globe.

How can I contact Vericel?

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.vcel.com. The biotechnology company can be reached via phone at (617) 588-5555, via email at ir@vcel.com, or via fax at 617-588-5554.

This page (NASDAQ:VCEL) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -